However, in ESCC patients, the angiogenesis pathway, EMT, and cell proliferation-related pathways, such as E2F/MYC targets, and tumorigenesis-related pathways, such as KRAS signaling and P53 pathways, were all significantly enriched in the low RAD21 expression group. The gene discussed is TP53; the disease is esophageal squamous cell carcinoma.